Cash, cash equivalents, and short-term investments at March 31, 2009 were $325.3 million.
Conference Call to Discuss First Quarter 2009 Financial Results
A conference call to review results will be held on May 6, 2009 at 2 PM Pacific Time.
Details are below:
Howard Robin, president and chief executive officer, and John Nicholson, chief financial officer, will host a conference call beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT) on Wednesday, May 6, 2009.
To access the conference call, follow these instructions: Dial: 888.396.2369 (U.S.); 617.847.8710 (international) Participant Passcode: 82263149 (Howard Robin is the host)
An audio replay will also be available shortly after the call and will remain so through May 20, 2009.
To access the replay, follow these instructions: Dial: 888-286-8010 (U.S.); 617-801-6888 (international) Participant Passcode: 19053055
Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugate technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own high-value therapeutics that addresses unmet medical needs
|SOURCE Nektar Therapeutics|
Copyright©2009 PR Newswire.
All rights reserved